Company intelligence / Profile preview
Alebund Pharmaceuticals
Shanghai, Shanghai, Chinaalebund.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Alebund’s lead candidate AP306 received Breakthrough Therapy Designation from China’s NMPA for hyperphosphatemia in CKD. The company has multiple clinical-stage assets targeting major renal diseases. AP306 is entering pivotal global studies; another iron-based binder is approaching NDA submission. The pipeline includes both small molecules and biologics with best-in-class or first-in-class potential.
- Therapeutic areas
- Nephrology
- Modalities
- Small moleculesBiologics/antibodiesIron-based phosphate bindersPan phosphate transporter inhibitors
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Chugai Pharmaceutical Co., Ltd. – option/license agreement for AP306/EOS789.Lilly Asia Ventures – incubator/investor relationship.
Beyond the preview
Go deeper on Alebund Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alebund Pharmaceuticals.